Programmed death-ligand 1 (PD-L1) expression is determined in formalin-fixed paraffin-embedded tissue slides by immunohistochemistry. All viable tumor cells are included (minimum 100 viable tumor cells). The pathologist evaluates using light microscopy. PD-L1 expression is determined as Tumor Proportion Score (TPS): percentage viable tumor cells showing partial or complete membrane staining. Cytoplasmic staining is excluded. Immune cell staining is reported separately (not included in TPS). Please confirm that 88360 is appropriate. ...
Subscribe or sign in to view the full article.
Article Overview
This article explains a pathology-focused PD-L1 immunohistochemistry topic and addresses whether a particular CPT reporting approach is appropriate. It is relevant to pathology, molecular diagnostics, and medical coding professionals who work with tumor biomarker testing, specimen interpretation, and assay reporting. The article also touches on scoring concepts used in PD-L1 testing and discusses the general coding category associated with manual quantitative or semiquantitative morphometric analysis.
Why This Topic Matters
PD-L1 testing is widely used in oncology pathology, and coding for its reporting must align with how the analysis is performed and documented. This article helps readers understand the clinical and coding context surrounding PD-L1 immunohistochemical evaluation without needing to infer details from the laboratory workflow alone.
What You Will Learn
- How PD-L1 immunohistochemical testing is described in a pathology context.
- How PD-L1 scoring concepts are framed at a high level.
- How the article connects a pathology workflow to a CPT coding question.
- What general type of coding issue is being addressed for manual morphometric analysis.
Who Should Read This
- Pathologists
- Pathology coders
- Medical coders
- Oncology billing staff
- Laboratory professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com